Free Trial
NYSE:EW

Edwards Lifesciences (EW) Stock Price, News & Analysis

$87.46
-2.75 (-3.05%)
(As of 05/23/2024 ET)
Today's Range
$87.05
$90.20
50-Day Range
$84.23
$95.56
52-Week Range
$60.57
$96.12
Volume
2.46 million shs
Average Volume
3.57 million shs
Market Capitalization
$52.70 billion
P/E Ratio
37.70
Dividend Yield
N/A
Price Target
$94.31

Edwards Lifesciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
7.8% Upside
$94.31 Price Target
Short Interest
Healthy
1.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.86mentions of Edwards Lifesciences in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$16.03 M Sold Last Quarter
Proj. Earnings Growth
12.27%
From $2.77 to $3.11 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.51 out of 5 stars

Medical Sector

84th out of 915 stocks

Surgical Appliances & Supplies Industry

3rd out of 18 stocks

EW stock logo

About Edwards Lifesciences Stock (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Stock Price History

EW Stock News Headlines

Edwards Lifesciences (NYSE:EW) Raised to "Buy" at Citigroup
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Today
5/23/2024
Next Earnings (Estimated)
7/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
28176E10
Employees
19,800
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$94.31
High Stock Price Target
$107.00
Low Stock Price Target
$57.00
Potential Upside/Downside
+7.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
19 Analysts

Profitability

Net Income
$1.40 billion
Pretax Margin
26.19%

Debt

Sales & Book Value

Annual Sales
$6.14 billion
Cash Flow
$2.67 per share
Book Value
$11.93 per share

Miscellaneous

Free Float
594,826,000
Market Cap
$52.70 billion
Optionable
Optionable
Beta
1.10

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

EW Stock Analysis - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price target for 2024?

19 Wall Street analysts have issued 12-month target prices for Edwards Lifesciences' shares. Their EW share price targets range from $57.00 to $107.00. On average, they expect the company's share price to reach $94.31 in the next year. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2024?

Edwards Lifesciences' stock was trading at $76.25 at the start of the year. Since then, EW shares have increased by 14.7% and is now trading at $87.46.
View the best growth stocks for 2024 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,630,000 shares, an increase of 30.5% from the April 15th total of 7,380,000 shares. Based on an average daily volume of 3,550,000 shares, the short-interest ratio is currently 2.7 days. Currently, 1.6% of the company's shares are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings data on Thursday, April, 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The medical research company earned $1.60 billion during the quarter, compared to analysts' expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a trailing twelve-month return on equity of 22.86%.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its second quarter 2024 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of 0.670-0.710 for the period, compared to the consensus earnings per share estimate of 0.700. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.6 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.79%), Bank of New York Mellon Corp (3.15%), Price T Rowe Associates Inc. MD (1.08%), Janus Henderson Group PLC (0.88%), Champlain Investment Partners LLC (0.49%) and Capital International Investors (0.37%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
This page (NYSE:EW) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners